These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27784557)

  • 21. A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride.
    Issa MM; Runken MC; Grogg AL; Shah MB
    Am J Manag Care; 2007 Feb; 13 Suppl 1():S10-6. PubMed ID: 17295600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 5-Alpha-Reductase Inhibitors and Combination Therapy.
    Füllhase C; Schneider MP
    Urol Clin North Am; 2016 Aug; 43(3):325-36. PubMed ID: 27476125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Review of the FAERS Data on 5-Alpha Reductase Inhibitors: Implications for Postfinasteride Syndrome.
    Baas WR; Butcher MJ; Lwin A; Holland B; Herberts M; Clemons J; Delfino K; Althof S; Kohler TS; McVary KT
    Urology; 2018 Oct; 120():143-149. PubMed ID: 29960004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits.
    Montorsi F; Alcaraz A; Desgrandchamps F; Hammerer P; Schröder F; Castro R
    Prostate; 2009 Jun; 69(8):895-907. PubMed ID: 19267353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Persistent Sexual and Nonsexual Adverse Effects of Finasteride in Younger Men.
    Irwig MS
    Sex Med Rev; 2014 Jan; 2(1):24-35. PubMed ID: 27784541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of chronic 5-alpha-reductase inhibitor (dutasteride) treatment on rat erectile function.
    Pinsky MR; Gur S; Tracey AJ; Harbin A; Hellstrom WJ
    J Sex Med; 2011 Nov; 8(11):3066-74. PubMed ID: 21834872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Persistent sexual side effects of finasteride for male pattern hair loss.
    Irwig MS; Kolukula S
    J Sex Med; 2011 Jun; 8(6):1747-53. PubMed ID: 21418145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sexual, physical, and overall adverse effects in patients treated with 5α-reductase inhibitors: a systematic review and meta-analysis.
    Zhang JJ; Shi X; Wu T; Zhang MD; Tang J; Yin GM; Long Z; He LY; Qi L; Wang L
    Asian J Androl; 2022; 24(4):390-397. PubMed ID: 34747724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?
    Carson CC
    BJU Int; 2006 Apr; 97 Suppl 2():39-43; discussion 44-5. PubMed ID: 16507053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sexual side effects of 5-α-reductase inhibitors finasteride and dutasteride: A comprehensive review.
    Fertig RM; Gamret AC; Darwin E; Gaudi S
    Dermatol Online J; 2017 Nov; 23(11):. PubMed ID: 29447628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
    Musquera M; Fleshner NE; Finelli A; Zlotta AR
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1073-9. PubMed ID: 18588452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sexual Dysfunction Related to Drugs: a Critical Review. Part V: α-Blocker and 5-ARI Drugs.
    La Torre A; Giupponi G; Duffy D; Conca A; Cai T; Scardigli A
    Pharmacopsychiatry; 2016 Jan; 49(1):3-13. PubMed ID: 26569417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 5α-Reductase inhibitors in androgenetic alopecia.
    Yim E; Nole KL; Tosti A
    Curr Opin Endocrinol Diabetes Obes; 2014 Dec; 21(6):493-8. PubMed ID: 25268732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 5α-Reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia.
    Chou CH; Lin CL; Lin MC; Sung FC; Kao CH
    J Endocrinol Invest; 2015 Jul; 38(7):799-805. PubMed ID: 25778849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Five-alpha reductase inhibitors and risk of prostate cancer among men with benign prostatic hyperplasia: A historical cohort study using primary care data.
    Thakrar DB; Douglas IJ; Smeeth L; Bhaskaran K
    Wellcome Open Res; 2023; 8():295. PubMed ID: 38774490
    [No Abstract]   [Full Text] [Related]  

  • 36. Impact of preoperative 5α-reductase inhibitors on perioperative blood loss in patients with benign prostatic hyperplasia: a meta-analysis of randomized controlled trials.
    Zhu YP; Dai B; Zhang HL; Shi GH; Ye DW
    BMC Urol; 2015 Jun; 15():47. PubMed ID: 26032962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of 5-Alpha Reductase Inhibitors in Dermatology: A Narrative Review.
    Escamilla-Cruz M; Magaña M; Escandón-Perez S; Bello-Chavolla OY
    Dermatol Ther (Heidelb); 2023 Aug; 13(8):1721-1731. PubMed ID: 37432644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications.
    Seftel A; Rosen R; Kuritzky L
    Int J Impot Res; 2007; 19(4):386-92. PubMed ID: 17377613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The post-finasteride syndrome: possible etiological mechanisms and symptoms.
    Leliefeld HHJ; Debruyne FMJ; Reisman Y
    Int J Impot Res; 2023 Sep; ():. PubMed ID: 37697052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
    Rittmaster RS
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):389-402. PubMed ID: 18471794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.